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REVIEW
culture systems or bioreactors for large tissue defects need 
to be designed in such a way as to avoid hypoxic and necrotic 
conditions and may require a complex vascular network to 
deliver nutrients and oxygen to cells (1).
To overcome the nutrient diffusion limit for tissue/organ 
engineering applications, hollow fiber bioreactors (HFBs) 
were designed with the aim of mimicking the native vascula-
ture in living tissues. HFB geometry offers a series of benefits, 
including compactness, a large mass exchange surface area 
to bioreactor volume ratio around 30 cm2/cm3. HFBs have ex-
cellent mass transfer properties and provide cell protection 
from mechanical stresses. Other advantages rely on the vir-
tual absence of the cell wash out, the ability for the immune 
isolation of xenogeneic cells and the possibility for scaffolding 
the cells with membranes (2-4).
Here, we review the existing literature on HFBs from an en-
gineering standpoint. To this purpose, we classified HFBs into 
2 main categories: cylindrical hollow fiber bioreactors (cHFBs) 
and rectangular hollow fiber bioreactors (rHFBs). For each 
group, we report on the main design and operating parameters 
as well as on their main applications at the tissue/organ level, 
focusing on the experimental and computational outcomes. 
Finally, we critically discuss the perspectives of HFBs as in vitro 
models for vascularized tissue and organ engineering.
Hollow fiber bioreactor configurations
Several HFB configurations have been proposed for or-
gan and tissue engineering. We classified HFBs into 2 main 
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Introduction
All organs in the body have a vasculature network whose 
main function is to maintain homeostatic conditions in the 
tissue for optimal function and survival of the cells (Fig. 1A). 
Thanks to the hierarchical architecture of the circulation sys-
tem, blood vessels enable the distribution of energy in the body, 
the transportation of different nutrient or signal molecules and 
the removal of waste products arising from the cell metabolism 
(Fig. 1B, C). To ensure viability in vivo, cells are generally im-
mersed in a three-dimensional (3D) environment and located 
no more than approximately 100 to 200 µm from microvessels 
or capillaries, which supply them with oxygen and nutrients.
It has been reported that the cell region beyond a 100-μm 
thick layer cannot be supported in vitro via diffusion under 
static conditions (1). The diffusive mass transport limits the 
size of engineered 3D organs and tissues. Therefore, dynamic 
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in nutrient transport by diffusion, which is often an obstacle to engineer sizable constructs in vitro. This work 
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perimental models and computational studies as predictive tools for designing innovative, dynamic culture sys-
tems. Finally, we discuss future perspectives on hollow fiber bioreactors as in vitro models for tissue and organ 
engineering applications.
Keywords: Computational models, Hollow fiber bioreactors, Mass transport, Organ engineering, Tissue engineer-
ing, Vascularization
Accepted: January 18, 2016
Published online: February 22, 2016
corresponding author:
Michele M. Nava
Department of Chemistry, Materials  
and Chemical Engineering “Giulio Natta”
Politecnico di Milano
Piazza Leonardo da Vinci, 32
20133 Milan, Italy
michele.nava@polimi.it
Hollow fiber bioreactors in tissue engineering2 
© 2016 The Authors. Published by Wichtig Publishing
categories according to the mass exchange surface area to 
bioreactor volume ratio and the modularity of such systems. 
In cHFBs, the surface to volume ratio is higher if compared 
to its counterpart in rHFBs. Rectangular HFBs, on the con-
trary, might be more suitable for a potential subcutaneous 
implantation due to their limited hindrance/size, whereas 
cHFBs may be more suitable as external support systems. In 
terms of modularity, rHFBs may be designed by small, cell-
laden modules (i.e., building blocks) to be assembled into 
larger constructs. This bottom-up approach makes it possible 
to mimic the heterogeneity of the culture environment and 
the complexity of some organs that have repetitive modules 
(5-7). According to the above-mentioned criteria, we grouped 
HFBs into cHFBs and rHFBs. Examples of the use of these 2 
configurations are presented in Tables I and II, respectively.
Cylindrical HFBs are composed of a bundle of parallel, semi-
permeable, hollow fibers (HFs) assembled in a cylindrical hous-
ing or in a cartridge. Cylindrical HFBs have a specific versatility 
due to multiple possible paths for the medium flow and cell 
location. The medium may flow through HFs and/or through 
the extracapillary space (ECS) (Fig. 2A). In Figure 2B, we show 
the cross-section view of the bioreactor Ab, and the localization 
of the HFs, whose size (e.g., inner radius Rif, outer radius Rof), 
number N
HF
, fiber interdistance Δs, and arrangement may vary 
according to the tissue/organ application (Fig. 2C).
Concerning cell location, the cells can be directly seeded on 
the outer surface (Fig. 3A) or in the internal lumen (Fig. 3B) of 
the HFs, while the medium flows in the internal HF lumen. The 
nutrient transport depends on the ratio between the convec-
tive transport in the liquid phase and the diffusion through the 
HF to cells (Fig. 3A). Conversely, as shown in Figure 3B, cells can 
be directly exposed to the culture medium. In such a configura-
tion, cells are subjected to shear stresses, while nutrients are 
provided mostly by convective transport. In further configura-
tions, cells can be cultured in a gel (Fig. 3C) or in a porous scaf-
fold (Fig. 3D) filling the ECS, while perfusion occurs in the HF 
lumen. Finally, cells can be cultured both on the internal and/
or the external surface of the HFs (Fig. 3E).
Fig. 1 - Scheme of native tissue vascularization. (A) Vascularized organs/tissues. (B) Zoomed view the capillary blood network within a 
tissue. (c) Blood capillary: the blood flows through the capillary and nutrients are delivered to the tissue while waste are removed. The 
diagrams show the variation of nutrient and waste concentration in both the capillary and the tissue.
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TAbLE II - Experimental studies relevant to Rectangular hollow fiber bioreactors (rHFBs)
Tissue/organ  
application
bioreactor scaffold and  
HF materials
Dimensions (mm) culture condition Measured variables Refs.
Vascularization  
in epithelium
Fig. 4 HF = collagen-gel  
sheets
Rif = 0.150, Rof = 0.650 Human CM and  
human umbilical 
vein ECs  
Q = 0.5 mL/min
Vascular network formation  
in cell sheets in vitro (n static 
and perfused condition both  
in presence of VEGF and bFGF 
or VEGF) and in vivo
(6, 7)
Wound dressing Fig. 4 HF = PES Rif = 0.15, NHF = 33-35 
Surface area = 0.09425 
cm2cm-1 Ab = 1600 mm
2 
L = 40, H = 40
Animal test  
in vivo
Recombinant human growth 
and differentiation factor-5 
(rhGDF-5)
(22)
Fig. 2 - Sketch of a hollow fiber bioreactor (HFB). (A) Side view of a HFB: it is composed of a bundle of hollow fibers (HFs) assembled in a 
cylindrical shell. The fluid may flow both through the HFs internal lumen and/or in the extracapillary space (ECS). (B) Cross-section of a 
HFB. Ab stands for the cross-section area, Rb is the bioreactor radius, Δs is inter fiber spacing and NHF is the number of HFs. (c) Zoomed 
view of a HF as a Krogh cylinder. Rif and Rof are the inner and the outer HF radii, respectively and RK is the Krogh cylinder radius. RK is 
calculated as the half of the distance between the center 0 of two HFs when embedded in a cylindrical shell or cartridge. R
K
 is used for 
modeling purposes.
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For example, in many cHFB applications, cells were cul-
tured in a gel in the ECS while the culture medium flows in the 
HFs. This kind of operating cHFB was used in particular to en-
gineer bone and cartilage tissues (3, 8-14), for drug screening 
(15) and testing (4) (Fig. 3A, C, D). Concerning liver engineer-
ing, cells were cultured on the external surface of the HFs and 
the culture medium flowed in the lumen (16, 17) (Fig. 3A). 
Regarding other cHFB applications such as hemopurification 
(18) and a bioartificial kidney (19), a 2-fluid flow system 
was designed with cells cultured in the inner surface of HFs 
(Fig. 3B). In bone (13), liver and for muscle tissue engineering 
(20), several applications were based on the use of 3D poly-
meric scaffolds in the ECS of cHFBs (Fig. 3D). Finally, cHFB con-
figurations allowed the culturing of 2 types of cells physically 
separated by the HFs (Fig. 3E), for example, in blood brain 
barrier (BBB) bioreactors (21).
Rectangular HFBs are composed of a hollow fiber mem-
brane embedded within a scaffold with a rectangular shape 
(Fig. 4A). As shown in the cross-section view Ab of the rHFB 
(Fig. 4B), the localization of HFs, as well as their size (e.g. the 
inner radius Rif, the outer radius Rof), number and inter-dis-
tance Δs, may vary according to the tissue/organ application. 
In this configuration, the medium flows through the HFs in-
ternal lumen and one or more cell sheets can be cultured 
on the top of the polymeric hollow fiber membrane scaffold 
(Fig. 4C, D). This configuration was used to model wound 
repair in vivo (22) and the angiogenesis occurring in cardiac 
tissue both in vitro and in vivo (6, 7).
Hollow fiber fabrication and characterization
Hollow fibers can be fabricated by extrusion or wet phase 
inversion spinning techniques (23). Wet phase inversion spin-
ning is the most widely used technique to fabricate HFs for 
the purposes of bioartificial organs and tissue engineering. 
Other HF manufacturing techniques include electrospinning 
and dip coating methods (23).
The HF fabrication parameters affect their mechanical 
and transport properties, including pore morphology and 
permeability (23). Actually, HF pore morphology and size act 
as a selective barrier for molecules that have a steric hin-
drance larger than a given pore dimension. The membranes 
are classified according to molecular weight cutoff (MWCO), 
which is defined as the molecular weight of the species that 
Fig. 3 - Configurations of cHFBs according to the cell location. The cells can be cultured on (A) the outer wall of the HFs, (B) on the inner wall 
of the HFs. The cells can be (c) embedded in a hydrogel filling the ECS or (D) cultured in a porous scaffold with embedding HFs. (E) Cells can 
be placed both on the inner and on the outer surface of the HFs.
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is 90 percent retained by the membrane (24). According to 
the manufacturing process, the HF MWCO ranges from of 
6 to 190 kDa (Tab. I). The MWCO parameter is commonly 
used to design immune selective barriers to prevent the pas-
sage of immune-competent species (24). Concerning the 
material types, several synthetic polymers were used both in 
the cHFB (Tab. I) and in the rHFB (Tab. II) configurations. The 
employed polymers in cHFBs were polyethersulfone (PES), 
cellulose acetate (CA), poly(lactic-co-glycolic acid) (PGLA), 
polypropylene (PP), poly(ε-caprolactone) (PCL) for bone tis-
sue engineering applications. In addition, polysulfone (PSF) 
and PES were employed to manufacture HFs for bioartificial 
liver, kidney and pancreas devices. Finally, PP was used for 
BBB and other applications, including drug screening (Tab. I). 
All these materials can be processed alone or in blends for 
HF fabrication. However, polymer blending may enhance 
the HF mechanical properties, the degradation rate and the 
hydrophobicity/hydrophilicity for specific applications. In 
the rHFB configuration, HFs were manufactured by using PES 
embedded in collagen gels as a biodegradable polymer or 
scaffolding material (Tab. II).
Design and operating parameters of hollow fiber  
bioreactors
The design and the optimization of the operating param-
eters in the HFBs are crucial to increase the ability to mimic 
the in vivo environment in bioreactor cultures. These param-
eters include the HFB geometry (e.g., the inner and outer HF 
radii Rf and Rof, the interfiber spacing Δs, the bioreactor radius 
Rb, and length L) (Fig. 2). Moreover, the medium culture flow 
parameters need to be carefully optimized. For example the 
flow regime (i.e., steady or pulsatile), the perfusion rate and 
the fluid properties. The HF porous membrane parameters, 
including the porosity, the pore size, the hindrance factor, the 
MWCO, the permeability and the membrane physicochemical 
properties, affect the bioreactor performance as well. Finally, 
mass transport parameters relevant to oxygen, nutrients and 
waste species as well as the culture conditions (e.g., the cell 
type, the cell passage and the cell-seeding density) are other 
important operating parameters in HFB cultures to be consid-
ered. On the basis of the existing literature, the laminar flow 
regime was extensively adopted in experimental studies due 
Fig. 4 - Rectangular hollow fiber bioreactors. (A) Sketch of an rHFB composed of parallel HFs embedded in scaffold surrounded by a rectan-
gular shell. (B) Cross-section view. Δs is inter fiber spacing, Rif and Rof are the inner and the outer HF radii, respectively. (c) Configuration of 
a rectangular hollow fiber bioreactor in which cells are seeded on the top of hollow fiber scaffold. The fluid flows through the hollow fibers 
and mass transport may occur through the scaffold. (D) Vessels formation in time within the scaffold by adding layers of ECs during culture 
(6, 7) (from 1 to 4).
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to the low shear stresses exerted on cells. This allows the cell 
wash out from the culture substrate to be prevented (Tabs. I 
and II).
cylindrical hollow fiber bioreactors for tissue and  
organ engineering
Three-dimensional tissues
Natural tissues, such as bone tissue, are highly vascularized. 
Although viable large-tissue bone grafts of several millime-
ters can be obtained in perfused bioreactors, several limita-
tions need to be overcome. In particular, an adequate mass 
transport to the cells, especially those cells embedded in the 
middle of the constructs (25). Under diffusion-limited culture 
 conditions, the size of engineered viable bone tissues is less 
than 0.5 mm thick due to the mass exchange of nutrients and 
oxygen, which takes place solely by molecular diffusion (26, 27). 
To overcome nutrient diffusion limitations, biological angio-
genesis is the primary requirement to generate dense tissues. 
However, angiogenesis remains a technical challenge in tissue 
engineering (9). Within this context, HFBs were designed to 
mimic the native blood capillary system in the aim to enhance 
the molecule transport and mass exchange between the fluid 
(i.e., medium) and the cell phase by introducing a velocity flow 
field (i.e., convective term). Such systems are illustrated in 
Figure 3C, D.
In the realm of bone tissue engineering, the use of cHFBs 
was widely investigated. For example, Ye and colleagues (26) 
proposed a cHFB configuration like the one shown in Figure 
3C. It was demonstrated that such cHFB layouts induced 
significantly greater cell viability, proliferation and a more 
bone-like cellular morphology when compared to constructs 
cultured under nonperfused conditions (Tab. I).
Hadjizadeh’s group introduced an innovative scaffold for 
cHFB for growing bone and viable tissue constructs on a lab-
oratory scale. The form of this scaffold consisted of a sheet 
with parallel channels that could either be rolled to fit a cHFB 
cartridge by maintaining parallel hollow fibers, or kept in 
a flat, rectangular membrane to be used as an rHFB (13) 
(Fig. 3D). In this configuration, the polymeric scaffold and 
the HFs were fabricated in the same material (PCL). The cell 
adhesion and viability tests showed that this configuration 
possessed good potential for the engineering of large-scale, 
vascularized tissue constructs (Tab. I). In cHFB cartridges 
(Fig. 2C), positron emission tomography (PET) was used as 
a noninvasive method for the fluid flow visualization. It was 
observed that the spatial distribution of the fluid streamlines 
was more homogeneous under pulsatile condition (75 beat/
min) if compared to the steady laminar flow condition (Q = 
70 mL/min) (28) (Tab. I).
The effect of the perfusion regime (i.e., pulsatile and Star-
ling low to high) on solute transfer and cell viability and dis-
tribution in cHFBs having a configuration shown in Figure 3C 
were also investigated. After 12 days of culture at high Starling 
flow, a homogeneous cell density restricted to a region of di-
mensions of about 2.5 cm in length and 0.6 cm in diameter in 
engineered bone constructs was observed. The rest of the cel-
lularized scaffold of an overall length L = 9 cm, has shown a less 
homogeneous cell density, far from the natural bone (29, 30).
To overcome the limitations of nutrient diffusion in large 
3D tissue constructs, a novel HFB integrated with a 3D poly-
meric macroscopic porous scaffold (pore size = 500 µm) in 
the configuration shown in Figure 3D was reported. Mouse 
premyoblasts (C2C12) were investigated both under static 
and dynamic conditions with a different number of HFs (2, 
4 and 8) embedded in constant-volume, polymeric, porous 
 scaffolds. It was demonstrated that cell homogeneity and 
proliferation in the cHFB with 4 HFs was significantly greater 
compared to the other configurations. In the cHFB with 8 HFs, 
the seeding efficiency and the cell proliferation decreased 
due to a reduction in the available space in the porous scaf-
fold. In the cHFB with 2 HFs, despite the greater available 
space for cells to grow, the distance between fibers Δs, and 
therefore the relatively high characteristic diffusion length of 
nutrients, affected cell viability and proliferation (20) (Tab. I).
bioartificial organs
HFBs were largely used as bioartificial organs (BAOs) with 
the aim of temporarily supporting, or potentially substituting/ 
replacing vital organ functions of the malfunctioning liver, 
kidney and pancreas. In such applications, HFs should not be 
biodegradable and should support cell adhesion as a scaffold. 
Moreover, on the one hand, HFs have to act as an immuno-
isolation barrier, but on the other hand, they have to allow 
mass exchange between the fluid and the cell phase. Hence, 
the pore size of the HF membranes must be small enough to 
isolate the embedded exogenous cells but sufficiently large 
to allow appropriate mass transfer of nutrients to cells and 
removal of waste metabolites (23, 31-34).
Concerning liver tissue engineering, cHFBs configured 
as in Figure 3A were widely investigated. Such bioreactors 
aimed at increasing the oxygen supply to the hepatocytes 
and enhancing their proliferation and metabolic activity. Liv-
er cells were cultured as aggregates in the ECS or on the HF 
outer surface, while the medium (e.g., blood, plasma or me-
dium) flowed in the HF internal lumen (35). The functionality 
of such devices was demonstrated in an in vivo rabbit model 
with fulminant hepatic failure (36).
Regarding cHFB bioartificial liver (BAL) applications, a 
further configuration was investigated (Fig. 3D). The device 
was composed of a 3D polymeric scaffold (i.e., PU foam) in-
tegrated with HFs. In this system, cells were cultured both in 
the ECS and on the outer HF surfaces (Fig. 3D). In this in vitro 
study, the authors have shown that this cHFB allowed bet-
ter mass transfer, improved cell distribution and liver-specific 
functions of hepatocytes when compared to an ordinary HFB 
without the polymeric scaffold (37) (Tab. I).
Finally, a new design for BAL consisting of a crossed HFB 
was developed (16). The culture system was composed 
of PolyEtherEtherKetone (PEEK)-HFs and PES-HFs in an al-
ternating manner. These 2 HF types had different MWCO, 
physicochemical and permeability properties. The PEEK-
HFs provided cells with an oxygenated medium containing 
nutrients and metabolites, whereas the PES-HFs removed 
catabolites from cell compartments, mimicking the in vivo 
hepatic perfusion (Fig. 5). This new layout has shown good 
results in terms of hepatic functions (i.e., concentrations of 
albumin, urea and diazepam).
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© 2016 The Authors. Published by Wichtig Publishing  
Concerning renal assist devices (RADs), several efforts 
were made with the aim of designing devices to support/re-
place kidney functionalities. Humes et al presented the first 
concept of using HFs for renal cells in 1999 (38, 39). Porcine 
renal proximal tubule cells (PTCs) were cultured on the inner 
surface side of a single HF. In a further work, they scaled up 
this single HF to a cHFB system where cells were still cultured 
in the intraluminal space of the HF. The intraluminal space 
was perfused with culture medium, while the ECS was filled 
with culture medium (i.e., no perfusion) (Fig. 3B). They mea-
sured the mass transport and metabolic parameters, includ-
ing albumin, bicarbonate, glucose and amino acids. Notably, 
the cell construct showed active transport capabilities (i.e., 
reabsorption and secretory capabilities) and enhanced cell 
metabolic activity (18). They also tested this cHFB (Fig. 3B) as 
a kidney support system on animals and human patients with 
acute and chronic renal failure. They demonstrated improved 
metabolic performance and significant systemic effects in-
duced by the device. However, due to safety reasons, this ap-
plication had to be discontinued after 24 hours (40) (Tab. I). 
Ozgen et al succeeded for the first time in using a cHFB con-
figured like the one described above (Fig. 3B) to achieve some 
key functionalities of the kidney, such as the absorption of 
water, glucose and sodium in long-term culture (i.e., up to 
10 days) (41) (Tab. I). Oo et al used human PTCs in a cHFB 
arranged with 3 HFs (Fig. 3B). The results have shown that 
under perfusion conditions, human PTCs formed a functional 
epithelium in optimized double-coated HFs. (42) (Tab. I). In 
another work by the same group, a novel cHFB design of the 
bioartificial kidney application was presented (Fig. 3A). Hu-
man primary renal PTCs were cultured on the outer surface of 
the HFs to increase PES hemocompatibility. By this method, 
the authors showed that no HF coatings were required to ob-
tain a robust and functional renal epithelium. They also dem-
onstrated that this bioreactor was able to produce significant 
amounts of interleukins, known as immunomodulatory mol-
ecules (43) (Tab. I). However, many limitations still need to 
be overcome before clinical applications can be made of such 
constructs, including low metabolic, endocrine and immuno-
modulatory renal cell functions.
Concerning bioartificial pancreas devices, these systems 
can be designed as extravascular and intravascular devices, as 
well as microencapsulated Langerhans islets (3, 44). In such 
devices, HFs have to be conceived as an immunoisolation bar-
rier to both protect the transplanted Langerhans islets from 
the host rejection (i.e., acting as a barrier to immunoglobulins 
and other inflammatory molecules) and to allow nutrients, 
glucose and insulin to pass through the membrane towards 
cells. In this work, we are referring to the bioartificial pan-
creas in the cHFB configuration. For example, Gundersen et al 
theoretically and experimentally investigated the effect of ox-
ygen concentration on expansion of rat insulinoma cells and 
Fig. 5 - Top view of the crossed HF membrane bioreactor (described in ref. 16). Nutrients flow in PEEK-WC HFs lumen while a fluid flow for 
waste removal flows in PES HFs lumen. Cells are cultured in the extraluminal compartment.
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their ability to generate insulinin within a cHFB (Fig. 3C). The 
authors have shown that the HFB oxygenation did not affect 
glucose and oxygen consumption. Moreover, it was possible 
for insulinoma cells to be expanded and insulin production to 
be enhanced (45) (Tab. I).
The blood brain barrier
The blood brain barrier (BBB) presents a highly selective 
permeability barrier that separates the circulating blood from 
the brain extracellular fluid in the central nervous system. 
The blood brain barrier allows the passage of water, gases 
and lipid-soluble molecules by passive diffusion as well as the 
selective transport of molecules such as glucose and amino 
acids that are crucial to neural function (46, 47) (Tab. I).
Most in vitro BBB models proposed were based on co-cul-
tures of brain endothelial cells and astrocytes (or glial cells) 
cultured under static conditions. Besides co-culturing cells in 
static systems composed of 2 chambers (47), dynamic in vitro 
blood brain barrier (DIV-BBB) models were developed both 
as cHFBs and as microfluidic devices. Here we focus on cHFBs 
employed as DIV-BBB devices. Such devices consisted of a cy-
lindrical shell embedding HFs in which endothelial cells were 
cultured on the inner surface of the HFs while astrocytes and/
or pericytes were localized on the outer surface. The medium 
was flowed in the intraluminal space in laminar or pulsatile 
regime (Fig. 3E).
For example, DIV-BBBs were demonstrated to be a more 
powerful alternative to static in vitro BBB models because of 
their ability to recapitulate some features of both the physi-
ologic and nonphysiologic permeability properties of the BBB 
in vivo (48, 49) (Tab. I). A possible reason resides on the veloc-
ity field and the relevant shear stress field acting on cells that 
are able to better mimic the local physiological brain microen-
vironment (50-55). The morphology of cultured cells, the cell 
glucose consumption, the lactate production, the transen-
dothelial electrical resistance in HFs and other parameters, 
including the potassium transport and the HF permeability to 
drugs, were investigated.
To better mimic the physiological BBB, a further degree of 
complexity in DIV-BBB design was introduced. For example, 
to study the physiological and functional behavior of distinct 
segments of the human cerebrovascular network, a novel 
capillary-venule modular system composed of a combination 
of 2 DIV-BBBs was presented (56, 57). Both the venule and 
the capillary module were configured as cHFBs. In the venule 
module, ECs and human brain vascular smooth muscle cells 
(SMCs) were cultured on the inner and outer surfaces of the 
HFs, respectively. On the other hand, human primary brain 
microvascular endothelial cells (ECs) were co-cultured with 
human astrocytes on the outer surface of the HFs, in the cap-
illary module. A pulsatile flow was imposed to better mimic 
the fluid dynamic conditions in vivo. It was shown that ECs 
exposed to shear stress and fluid pressure had a comparable 
morphology and functionality with respect to their in vivo 
counterparts (56, 57). Thus, DIV-BBB models may be used to 
further investigate in vitro the immune cell trafficking across 
the BBB (Tab. I) A further field of research resides in phar-
maceutical drug screening and discovery (58, 59) to reduce 
laboratory tests on animals (60, 61) (Tab. I).
Rectangular hollow fiber bioreactors (rHFbs)
The rectangular HFB is a newly introduced approach in 
the field of HFBs (Fig. 4). This configuration is oriented to-
wards the implantation of bioreactor-generated tissues for 
therapeutic applications. Pletting et al reported a novel active 
wound dressing (AWD) based on HF membranes in a porcine 
wound model (22) (Tab. II). The rHFB was similar to the one 
shown in Figure 4B. A device of this sort was able to create 
a local medium-perfused environment, which enabled ad-
equate moisture levels in the wound. This is crucial for skin 
regeneration without scar tissue formation. Sakaguchi et al 
presented a new strategy to design vascularized 3D tissues 
using HFs. The device consisted of HFs embedded in collagen 
gel sheets (Fig. 4C). Cells cultured on the top of such sheets 
exhibited significant viability due to molecular diffusion 
through the collagen scaffold, and, interestingly, spontaneous 
angiogenesis was observed by cultivation of cell layers up to 
20 days (Fig. 4D) (6, 7). 
Other applications of HFbs
Besides organ and tissue applications, HFBs have been 
designed for other purposes. Pluripotent stem cells such as 
embryonic stem cells are a source for the production of differ-
ent cell types. HFBs are promising tools to scale up stem cell 
production to provide adequate cell numbers. For example, 
Roberts and colleagues used a cHFB (Fig. 3A) in a pilot study 
to expand human embryonic stem cells. They could expand 
60 million human embryonic stem cells up to 708 million cells 
during 8 days while maintaining their pluripotent phenotype 
and differentiation potential (62) (Tab. I). Furthermore, in 
Cadwell et al, a HFB was employed as an infection model study 
for antimicrobial pharmacodynamics and pharmacokinetics 
applications. In this model, the cells or the microorganisms 
were cultured in the ECS, while the culture medium was flowed 
in the lumen side as in Figure 3C (63) (Tab. I). Winkelmann et 
al fabricated HFs integrated into a microfluidic system for drug 
screening. This system combined several micro HFBs, each of 
them acting as a single tissue in order to make a multiorgan on 
chip, in analogy with the human body (15) (Tab. I).
Cylindrical HFBs were also used in cancer research thanks 
to the possibility of culturing cells at a high density and high 
proliferation rate, and therefore, of mimicking the in vivo tu-
mor microenvironment. For example, in Chiu et al, a cHFB in 
the configuration shown in Figure 3C was used for secretome 
analysis and cancer biomarker discovery. The authors report-
ed several advantages of using cHFBs in this field, including a 
high expansion and lower cell lysis rate and, consequently, an 
increased volume of samples to be analyzed when compared 
to static culture conditions (64) (Tab. I).
computational models in HFbs
Besides in vitro experimental models, several in silico stud-
ies have been developed to investigate optimal design param-
eters relevant to different cHFB configurations. An overview 
of these studies is presented in Table III. Such studies consist 
of two-dimensional (2D) or 3D computational fluid dynam-
ics (CFD) models governed by Navier-Stokes (NS) equations 
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TAbLE III - Computational studies relevant to cylindrical hollow fiber bioreactors (cHFBs)
Tissue/organ  
application
bioreactor Model parameters, 
dimensions (mm)
Model parameters,  
Medium flow and  
cell density
Predicted variables Refs.
Bone tissue
Fig. 3C
Experimental 
data from (26)
Rif = 0.1, Rof = 1.2  
Rk = 0.32
Rif/Rof = 0.833 L = 30
Ci = 2 × 10
6 cells/mL  
Q = 7.45 × 10-3 m/s  
Different Cf:  
Cf = 5 × 10
5 cells/m3  
Cf = 7 × 10
5 cells/m3  
Cf = 7 × 10
6cells/m3  
Cf = 2 × 10
7 cells/m3
2D steady/unsteady flow  
studies, oxygen and glucose  
concentration in HFs and  
ECS at different cell  
densities, fiber length,  
flow rate and reaction  
kinetic order (0, 1, 2)
(8)
Ci = 2 × 10
6 cells/mL  
Q = 7.45 × 10-4-7.45 × 10-2 m/s
(10)
Ci = 2 × 10
6 cells/mL  
Q = 7.45 × 10-3 m/s
(12)
Ci = 2 × 10
6 cells/mL  
Q = 7.45 × 10-3 m/s  
Different Cf:  
Cf = 2 × 10
6 cells/mL  
1 × 107 cells/mL 2 × 107  
cells/mL 3 × 107 cells/mL
(9)
Rif = 0.1, Rof = 1.2,  
Rk = 0.32  
Rif/Rof = 0.833 L = 3
Ci = 2 × 10
6 cells/mL  
Q = 7.45 × 10-3 m/s
(11)
Bone tissue Fig. 3C 
Experimental  
data from (26)
Rif = 0.1, Rof = 0.114 Rif/
Rof = 0.877, L = 30 Pore 
size = 0.2 × 10-3  
L = 30, Rb = 6.5  
NHF = 200 Δs = 0.65  
HF porosity = 0.2
Ci = 11379 cells/mL  
Ci = 1 × 10
12 cells/m3  
Cf = 10-160 × 10
6cells/mL  
Q = 14 mL/hr , 17 mL/min
2D, unsteady flow study cell popu-
lation dynamics (i.e. cell growth) 
oxygen and glucose concentration 
profiles in different fiber radius 
Rif, the outer fiber radius Rof, the 
bioreactor length L, the bioreactor 
radius Rb, the porosity, the inter 
fiber distance Δs, the hindrance 
factor and the cell density
(14)
Bone tissue Fig. 3D 
Experimental  
data from (13)
Rif = 0.5, Rof ≈ 0.65  
Rif/Rof = 0.76  
Rb = 11, L = 40
Cf = 50-150 × 10
12 cells/m3  
Q = 7.45 × 10-3 m/s
3D steady flow study oxygen, 
glucose and lactate concentration 
profiles in HFs, scaffold and ECS at 
different cell density, flow rate and 
porosity and permeability
(27)
Bone tissue Fig. 3C 
Experimental  
data from (26)
Rif = 0.10, Rof = 0.12,  
Rk = 0.320  
Rif/Rof = 0.833,  
Rb = 20 L = 250  
HF porosity = 0.5  
Permeability = 10-8 cm2
Ci = 3 × 10
7 cells/cm3  
Q = 0.1 m/s
2D, steady flow study cell density 
oxygen and glucose concentration 
profile
(69)
Bone tissue Fig. 3C Rif = 0.1, Rof = 0.2,  
RK ≈ 0.400  
Rif/Rof = 0.5  
HF porosity = 0.7  
L = 200
Neonatal rat CM,  
bovine chondrocytes,  
rat hepatocytes,  
osteoblasts  
Ci = 1 × 10
12 cells/m3
2D steady flow study oxygen and 
glucose concentration profiles
(4)
Bone tissue Fig. 3C Rif = 0.1, Rof = 0.19  
Rif/Rof = 0.526  
pore size = 0.1 × 10-3
pulsatile flow vs. Starling flow 
solute transfer by
(29)
Bioartificial liver Fig. 3C R
if ,PEEk-Wc
 = 0.9  
Rif ,PES = 0.73  
Rb = 15 L = 200  
NHF in each membrane 
system = 40
human hepatocytes 3D unsteady flow albumin, urea 
and diazepam concentration
(16)
Growth factor  
capture
Fig. 3A Rif = 0.350, Rof = 0.650 
Rif/Rof = 0.7  
L = 120, NHF = 20
bovine aortic ECs  
Cf = 0.3 × 10
6cell/cm2
1D steady flow (17)
To be continued
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coupled to the Maxwell-Stefan convection-diffusion-reaction 
equation to predict nutrient (e.g., glucose and oxygen) or ca-
tabolite (e.g., lactate) concentration fields in cHFBs (27, 65-
69). These models have been employed to study the transport 
phenomena at a resolved scale (i.e., in a representative do-
main of the whole culture system) and at the cHFB scale (i.e., 
at the laboratory scale). The concentration profiles of such 
variables were predicted at several varying culture param-
eters, including cell density, HF length, flow rate and reaction 
kinetics (of the order of 0, 1, or 2). Most of these computation-
al models were formulated according to Krogh’s model. The 
main assumption of Krogh’s model is that the fluid flow and 
the transport behavior associated with each fiber is identical. 
According to this assumption, a single fiber, which is represen-
tative of the whole bundle, is surrounded by an annulus (i.e., 
the ECS) along the direction of the fiber (14, 70). The Krogh 
cylinder radius R
K
, is defined as half of the distance between 
the center 0 of 2 HFs when embedded in a cylindrical shell 
or cartridge (Fig. 2C). The numerical results confirmed the 
experimental evidence: a sufficiently high nutrient concentra-
tion can be maintained in cHFBs to culture dense bone tissue. 
For example, in De Napoli et al, a computational 2D model 
of cHFBs under distinct fluid-dynamics conditions was devel-
oped to study the mass transport (e.g., oxygen and glucose) 
exchange, under Krogh’s cylinder assumption. The model pre-
dicted a moderate-to-high recirculation flow in the bioreactor 
and an enhanced solute transport to cells (4).
Some attempts accounting for cell growth were reported 
in the literature in order to improve the predictive ability of 
numerical modeling in HFBs. For example, a 2D computation-
al model based on a so-called dynamic, double-porous media 
model (PMM) for cHFB having a configuration shown in 
Figure 3C was developed. The convective transport was 
studied under unsteady conditions. This model included 
both the cell growth equation and the oxygen and glucose 
uptake rates. The contributions of several bioreactor designs 
and culture parameters, including the bioreactor geometri-
cal parameters (e.g., the inner fiber radius Rif, the outer fiber 
radius Rof, the bioreactor length L, the bioreactor radius Rb, 
the porosity, the inter fiber distance Δs, the hindrance fac-
tor and the cell density) (Fig. 2) to the performance of the 
bioreactor were simulated. The model was validated using 
previously published experimental results (26). The simula-
tions demonstrated that the process and design parameters 
of the HFB significantly affected nutrient transport and thus 
cell behavior over a long-term culture period (14) (Tab. I). A 
further work compared the suitability of 3 bioreactor config-
urations: a cHFB, a suspended tube and confined perfusion 
bioreactors. The results have shown that the cHFB was able 
to maintain a higher nutrient concentration at high cell densi-
ties when compared to the other 2 bioreactor configurations. 
This work also emphasized previous claims suggesting that 
the HFB may be a suitable configuration to engineer bone tis-
sues at high cell density (12) (Tab. I).
Concerning cHFBs as bioartificial liver devices, Hay et al 
developed a 1- dimensional (1D) steady state model to pre-
dict the oxygen consumption rate of hepatocytes in HFs 
(71). Within this field, a 3D numerical model based on the 
crossed HFB shown in Figure 5 was also developed. Results 
arising from this numerical model were in good agreement 
with experimentally measured data (e.g., concentration pro-
files of albumin, urea and diazepam). Moreover, their results 
Tissue/organ  
application
bioreactor Model parameters, 
dimensions (mm)
Model parameters,  
Medium flow and  
cell density
Predicted variables Refs.
Chondrocyte,  
cardiomyocyte  
cell and  
hepatocytes
Fig. 3C 
Experimental  
data from (26)
Rif = 0.1, Rof = 0.12,  
Rk = 0.8  
Rif/Rof = 0.833 L = 100  
Rif = 0.1, Rof = 0.12,  
Rk = 0.8 Rif/Rof = 0.833  
L = 100
Ci = 8.85 × 10
14 cells/m3  
Neonatal rat CM  
Cf = 10
12 cells/m3  
Primary rat hepatocytes  
Cf = 1.25 × 10
13 cells/m3  
Bovine chondrocytes  
Cf = 1.4 × 10
14 cells/m  
Pancreatic βTC3 cells  
Cf = 2.8 × 10
14 cells/m
2D steady, and unsteady fluid  
flow study Oxygen, glucose and 
lactate concentration profiles
(65, 68)
Bioartificial  
liver
Fig. 3A Rif = 0.320, Rof = 0.380  
Rif/Rof = 0.84 L = 450,  
NHF = 670  
Pore size = 0.2 × 10-3
primary hepatocytes  
Ci = 10 × 10
12 cells/bioreactor
1D steady flow and oxygen  
consumption rate in different  
inlet oxygen concentration
(71)
Bioartificial  
pancreas
Fig. 3C Rif = 0.1, Rof = 0.108  
Rif/Rof = 0.92  
Rk = 0.147
Rat insulinoma cells  
Q = 4.6 mL/min  
Ci = 35 × 10
6 cells/bioreactor  
Cell density up to 14 days  
Cf ≈ 57 × 10
3 cells/cm2  
PO2 19%  
Cf ≈ 38 × 10
3 cells/cm2  
PO2 10%
1D, oxygen consumption rate (45)
Rif = fiber inner radius; Rof = fiber outer radius; Rk = Krogh cylinder radius; Rb = bioreactor radius; L = bioreactor length; NHF = number of HFs; Ab = bioreactor cross-
section area; H = Bioreactor width; Q = flow rate; Ci = initial cell density; Cf = final cell density; CM = cardiomyocytes; ECs = endothelial cells.
TAbLE III - Continued
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have shown that the HFB configuration could significantly 
decrease limitations in mass transfer occurring within tissue-
engineered liver constructs (16).
conclusions and perspectives
The experimental and computational studies described 
in this review demonstrate a potential use of cHFBs in the 
production of 3D large tissues. These studies used mostly 
cHFBs in the configuration shown in Figure 3C. In addition, 
novel cHFBs in the form of the integrated scaffold with HFs, as 
shown in Figure 3D, achieved promising results. The compu-
tational models simulating fluid dynamics and mass transport 
in the cHFBs mostly considered a 2D, simplified geometry un-
der a steady state regime without accounting for cell behav-
ior (e.g., growth, migration, apoptosis and ECM production). 
These models employe various numerical techniques to study 
the oxygen distribution in HFBs. The parameters adopted are 
mostly averaged values and do not consider the geometric 
heterogeneity due to nonuniform cell growth. Some of the 
computational models account for the 3D geometry and un-
steady flow. Few of them consider cell dynamics. In most of 
the numerical models, there is a lack of experimental data to 
validate the computational predictions.
In the realm of BAOs, experimental research demonstrates 
that the use of cHFBs is effective in terms of cell functional-
ity, mass transfer and safety. Indeed, BAOs have already been 
used as external organs on patients for short periods (Fig. 3A, 
B or D). The configuration shown in Figure 3D has shown the 
most promising results in terms of cell proliferation, cell dis-
tribution and replacement of organ functions. The computa-
tional models in this field involve few parameters and have a 
limited predictive capability.
Cylindrical HFBs were used for DIV-BBB models (Fig. 3E). 
These bioreactors were designed to investigate the microvas-
culature system of the brain. It was stated that such devices 
can be successfully be used for translational and pharmaceu-
tical research instead of using laboratory animals (60, 61). In-
deed, cHFBs represent a beneficial alternative tool for in vitro 
BBB modeling. In addition, researchers have experimentally 
tried to obtain optimal operating parameters for culture cells 
in a bioreactor. In vitro models based on cHFBs have shown 
potential applicability in therapeutic fields such as cancer 
research, drug testing and pharmaceutics. Although an im-
provement in cell viability and number by means of cHFBs 
has been reported in the literature, such grafts cannot be 
applied in vivo. Indeed, the distribution of cells in large 3D 
tissues obtained by HFBs does not have sufficient homogene-
ity or uniform cell density when compared to native tissues. 
Therefore, such engineered constructs are not yet functional 
for therapeutic purposes.
So far, the potential to translate engineered tissues arising 
from HFBs into clinical applications does not exist yet. Cur-
rently, the highest potential of rHFBs is in the generation of 
3D models of tissue for biological research and drug delivery 
and testing.
In conclusion, there is a need for a more systematic knowl-
edge of the effect of HFB geometry on parameters related to 
cell viability and functionality, independent of the specific tis-
sue being regenerated. It is likely that computational models 
integrated with experiments will efficiently help in optimizing 
bioreactor design in terms of cell functionality, geometry and 
fluid dynamics.
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